This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

The World Market For Transdermal Drug Delivery

NEW YORK, Oct. 8, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

The World Market for Transdermal Drug Delivery

http://www.reportlinker.com/p01008895/The-World-Market-for-Transdermal-Drug-Delivery.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology

Transdermal (and related transmucosal) drug delivery is a well-established accepted route of administration for therapeutically beneficial medicines. There is no potential limit for the therapeutic area for development of transdermal systems. Some therapeutic areas stand out, including sex hormones and pain management, due to the successful combination of the individual drug molecules and available product technologies. The potential benefits that may be achieved using transdermal delivery include continuous, controlled release and absorption of medication into the body, avoiding presystemic metabolism that may occur following oral dosing, including both intestinal and hepatic first-pass metabolism, improving patient compliance by offering more convenient dosing regimens , such as once or twice weekly dosing, and the ability to quickly discontinue treatment by removal of the system.

This report, World Markets for Transdermal Drug Delivery is a comprehensive look at the transdermal/transmucosal drug delivery market is divided into two sections. The first section encompasses the pharmaceutical products that utilize the drug delivery technology. The second section encompasses drug delivery technology and the revenues earned from licensing that technology. Because drug delivery technology is an integral part of sales of pharmaceuticals and drug delivery technology cannot exist without pharmaceuticals, revenues have been reported that include pharmaceutical sales for products utilizing that technology.

This market is divided into two segments:

  • Market Size and Forecast for Transdermal Drug Delivery
  • Market Size and Forecast for Transmucosal Drug Delivery
  • Market Breakout by Region (US, Europe, Japan, ROW)
  • Review of Products on the Market
  • Market Breakout by Disease Treated (Cardiovascular, Hormones, Pain Management, Smoking Cessation, Other)
  • Market Breakout by Technology Revenues and Pharmaceutical Component Revenues
  • Profiles of Companies in the Market

The research conducted by Kalorama included comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. New technologies, market developments, and research and development trends and expenditures were identified through patent and database searches, as well as via interviews with key personnel. Person-to-person and telephone interviews were the primary method of gathering information. E-mail correspondence was also used in the interview process. Interviews with 18 key industry officials, trade association representatives, consultants, healthcare providers, and government personnel were compiled to form the primary basis of information—particularly revenue and market share data—presented in this report.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,055.87 -116.81 -0.68%
S&P 500 1,982.77 -11.52 -0.58%
NASDAQ 4,508.6880 -19.0010 -0.42%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs